Farallon Capital Management

GreenYellow Holding, founded in 2007 and headquartered in France, is engaged in the generation and supply of electricity through centralized power plants and decentralized photovoltaic projects. The company focuses on the development of solar energy solutions and offers services aimed at improving energy efficiency for a diverse clientele, including food and non-food retail sectors, government agencies, public utilities, and energy providers. By providing solar panels and energy management solutions, GreenYellow enables its clients to produce and optimize their energy consumption, significantly reducing costs while promoting the use of clean energy.

Beta Bionics is a biotechnology company based in Boston, Massachusetts, focused on advancing diabetes care through its innovative bionic pancreas system, known as the iLet. Founded in 2015, the company has developed a dual-chamber infusion pump that precisely delivers insulin and glucagon, allowing for autonomous management of blood sugar levels. The iLet has received breakthrough designation for its various configurations, including insulin-only, glucagon-only, and bihormonal uses, particularly in conjunction with Zealand Pharma’s dasiglucagon, a stable glucagon analog in a ready-to-use solution. By reducing the burden and cost associated with diabetes management, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

Ada is a global health company founded by doctors, scientists, and industry pioneers to create new possibilities for personal health. Ada’s core system connects medical knowledge with intelligent technology to help all people actively manage their health and medical professionals to deliver effective care. Ada is proud to collaborate with leading health systems and global non-profit organizations to carry out this vision. The #1 medical app for 130 countries, almost 20 million assessments have been completed since its global launch in 2016.

DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.

Swift Health Systems Inc. is a medical device company based in Irvine, California, that specializes in developing innovative orthodontic solutions. The company's flagship product, INBRACE, is an invisible orthodontic system designed to correct malocclusion by being discreetly positioned behind the teeth. INBRACE employs patented self-guiding technology that utilizes light and continuous forces to gently adjust teeth, minimizing discomfort and reducing the frequency of doctor visits. FDA registered, INBRACE aims to make orthodontic treatment more appealing by addressing common patient concerns and facilitating practice growth for clinicians. The system integrates digital treatment planning, computer modeling, and direct digital manufacturing to offer a scalable and personalized approach to a wide range of orthodontic cases, thereby raising the standard of care in the field.

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

Zepz operates WorldRemit, an online platform that facilitates international money transfers, allowing users to send funds to friends and family abroad. Established in 2009 and headquartered in London, WorldRemit provides a secure service accessible via computer, smartphone, or tablet. The platform enables users to send money to over 140 destinations, including countries in Africa, Asia, Europe, and the Americas. Recipients can receive funds through various methods, such as bank deposits, cash pickups, mobile money, and airtime top-ups. By offering a convenient and low-cost alternative to traditional money transfer services, WorldRemit has become a popular choice for millions of users looking to support their loved ones and manage their financial transactions effectively.

Zentera Therapeutics is a biopharmaceutical company.

POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, expertise in radioisotopes such as Actinium-225 (Ac-225) and Lutetium-177 (Lu-177), manufacturing technology and novel direct-to-patient targeting to revolutionize theragnostic drug development and radioligand commercialization.

GenapSys, Inc. develops innovative DNA sequencing technologies for applied genomic testing and medical sequencing. The company's primary product, the GenapSys Sequencer, utilizes electrical-based detection for single nucleotide incorporations, facilitating sequencing in various laboratory settings and automating clonal amplification. GenapSys offers solutions for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. Additionally, the company seeks to collaborate with local health agencies and researchers to enhance access to sequencing insights, particularly for controlling and mitigating outbreaks. The compact and portable nature of the sequencer allows it to operate from standard power sources, making it suitable for deployment in hospitals, airports, and public transportation hubs to provide rapid results for virus samples. Founded in 2010, GenapSys is headquartered in Redwood City, California.

BioTheryX, Inc. is a biopharmaceutical company based in Chappaqua, New York, that specializes in the development of therapies for hematological malignancies and other diseases. The company focuses on restoring protein homeostasis through innovative approaches such as Protein Homeostatic Modulators, which are small molecular glue cereblon binders with significant therapeutic potential. Additionally, BioTheryX is advancing targeted protein degradation technologies, including PROTACs, which utilize dual ligands to facilitate the degradation of specific proteins. The company also offers BTX-A51, an oral small molecule that acts as a multi-kinase inhibitor to target leukemic stem cells and suppress key oncogenic gene transcription. Founded in 2007, BioTheryX aims to expedite the delivery of effective therapies to patients with unmet medical needs by leveraging enhanced biology-driven models and clinically proven translational approaches.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services, which focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides morphologic analysis which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. has a strategic collaboration with Inivata Limited for the commercialization of its InVisionFirst-Lung liquid biopsy test in the United States. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

LUMICKS B.V. is a company that specializes in developing advanced equipment for dynamic single-molecule and cell avidity analysis, facilitating research in biology and cancer at the molecular and cellular levels. Founded in 2014 and headquartered in Amsterdam, with an additional office in Cambridge, Massachusetts, LUMICKS offers innovative technologies such as correlative optical tweezers-fluorescence microscopy systems and the C-Trap, which integrates optical tweezers with advanced imaging techniques. The company’s Acoustic Force Spectroscopy (AFS) enables the study of mechanical properties in biological systems, while its u-Flux microfluidics system allows for single-molecule experiments in controlled laminar flow environments. By enabling live measurements and imaging of molecular interactions, LUMICKS provides valuable insights into the fundamental causes of diseases, including cancer, and supports drug optimization efforts.

Theseus Pharmaceuticals is a Technology based company.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. Operating in the United Kingdom, European Union, and the United States, Orchard employs an autologous ex vivo gene therapy approach to transform patients’ hematopoietic stem cells into gene-modified products for treatment through a single administration. Its portfolio includes Strimvelis, the first approved gene therapy for adenosine deaminase-severe combined immunodeficiency (ADA-SCID), along with several products in clinical development targeting metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has a robust preclinical pipeline addressing various mucopolysaccharidosis types. Orchard collaborates with leading institutions in gene therapy, enhancing its research capabilities and clinical programs. Founded in 2015, Orchard Therapeutics continues to demonstrate a commitment to transforming the lives of patients through its advanced therapies.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, established in 2014. The company specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment for oncologists and their patients. By utilizing its TAm-Seq technology, Inivata enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through a simple blood sample. This non-invasive method, known as liquid biopsy, represents a significant advancement in cancer diagnostics, allowing for improved detection, monitoring, and treatment decision-making. Inivata has also formed a strategic collaboration with NeoGenomics, Inc. to further strengthen its capabilities in this field.

DarioHealth Corp. is a digital health company that specializes in developing and commercializing proprietary technology for laboratory testing via smartphones and mobile devices. Its flagship product, the Dario Smart Diabetes Management Solution, integrates a cloud-based software application with a compact blood glucose monitoring device. This solution enables users to manage their diabetes through real-time data tracking, coaching, and support, while also providing alerts and analysis of health trends. DarioHealth markets its products directly to consumers and through retail pharmacies, hospitals, and online channels. The company also offers a digital platform, DarioEngage, to enhance user engagement and support in managing chronic illnesses. Founded in 2011 and headquartered in Caesarea, Israel, DarioHealth emphasizes personalized, evidence-based interventions driven by data analytics and individual coaching, addressing various health concerns such as diabetes, hypertension, and weight management.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines using its innovative base editing technology. This technology allows for targeted alterations of single bases in the genome without creating double-stranded breaks in DNA, representing a potential advancement in genetic therapies. The company's pipeline includes programs aimed at treating serious diseases such as sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, and pediatric acute myeloid leukemia, as well as conditions like alpha-1 antitrypsin deficiency and certain central nervous system disorders. Beam Therapeutics is committed to providing life-long cures through its various approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Founded in 2017, Beam continues to build collaborations to enhance its research and development efforts.

Ikena Oncology is dedicated to bringing next generation oncology therapies to patients suffering from cancer. Ikena Oncology are committed to leveraging our unique understanding of the complex biologic pathways that drive the formation and spread of cancers to discover and develop novel, patient-directed therapies. Selecting patients for treatment in clinical studies with biomarkers we develop is at the core of our strategy.

FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.

Univercells SA, founded in 2013 and based in Gosselies, Belgium, specializes in the design, development, and implementation of single-use bioprocess solutions for biomanufacturing. The company offers a comprehensive range of services, including the design and construction of manufacturing facilities, as well as the maintenance and supply of bulk active pharmaceutical ingredients (APIs). With a focus on vaccines and biologics, Univercells employs innovative engineering techniques that significantly reduce investment needs by over 75% and lower production costs by up to 90%. Their approach integrates three manufacturing steps—cell culture under perfusion, clarification, and capture—into a simulated continuous mode, enhancing efficiency in the production of antibodies, proteins, and vaccines. Additionally, Univercells has established a strategic partnership with Takeda Pharmaceutical Company to further advance its capabilities in the biomanufacturing sector.

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, specializing in the development of innovative medicines targeting various diseases, including cardiovascular, central nervous system, inflammatory, and metabolic disorders. The company's pipeline features several investigational drugs, including Etrasimod, currently in Phase III trials for ulcerative colitis and Phase IIb/III for Crohn's disease, along with studies for atopic dermatitis. Additionally, Olorinab is in Phase IIb trials for abdominal pain associated with irritable bowel syndrome, while APD418 is in early Phase I trials for acute heart failure. Ralinepag is also undergoing Phase III trials for pulmonary arterial hypertension. Arena Pharmaceuticals has established collaboration agreements with various pharmaceutical companies, enhancing its research and development efforts. The company was founded in 1997 and has made significant strides in the biotechnology field, particularly in targeting G-protein-coupled receptors.

Longboard Pharmaceuticals delivers medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. Its proprietary pipeline includes multiple programs with broad clinical utility. Longboard is evaluating LP352, a next-generation 5-HT2C agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or DEEs. Longboard is also evaluating LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), and LP659, a centrally acting, next-generation, highly selective S1P receptor modulator.

Kesoram Industries Limited, based in Kolkata, India, is a diversified manufacturer established in 1919, originally as Kesoram Cotton Mills Ltd. The company operates primarily in the cement and rayon sectors, marketing its cement products under the Birla Shakti brand. Kesoram entered the rayon industry in 1959, and over the years, it expanded into the production of transparent paper and filament yarn. The company changed its name to Kesoram Industries Limited in 1986 to reflect its broadening business portfolio. Today, Kesoram generates the majority of its revenue from the cement segment, with a significant share of its operations focused on the Indian market.

AUTO1 Group GmbH operates a digital platform that connects buyers and sellers in the used car market, facilitating transactions in Europe and North America. Founded in 2012 and based in Berlin, the company sources used cars from original equipment manufacturers (OEMs), dealerships, and its own business units, which include AUTO1.com and Autohero.com. The platform provides a seamless experience for both individual customers and professional dealers, allowing them to trade used cars at transparent prices without the complexities of negotiation. AUTO1 Group has two main segments: Merchant, where used cars are sold to commercial dealers, and Retail, which focuses on sales to private customers. The company continues to expand its presence, operating in nearly 30 countries and offering a diversified inventory that enhances its marketplace capabilities.

Encoded Therapeutics, Inc. is a biotechnology company focused on developing precision gene therapies for severe genetic disorders. The company's innovative platform identifies sequences within the human genome that regulate gene expression through advanced screening and computational methods. Its therapy pipeline targets a variety of genetic and acquired disorders across multiple disease pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and headquartered in South San Francisco, California, Encoded Therapeutics aims to enhance treatment options available to medical practitioners, ultimately improving patient outcomes and quality of life.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, specializing in the development of specific and selective antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create novel monoclonal antibody and cell-based therapeutics. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate aimed at treating soft tissue and bone sarcoma, non-small cell lung cancer, and other tumors. BioAtla's pipeline also includes BA3021, targeting non-small cell lung cancer and melanoma, and BA3071, which addresses various cancers such as renal cell carcinoma and bladder cancer. The company's innovative approach enhances drug selectivity for cancer tissues, potentially improving safety and expanding treatment options for previously untreatable cancers. BioAtla holds over 150 issued patents and patent applications, underscoring its commitment to developing safer and more effective cancer therapies.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for autoimmune and neurodegenerative diseases that are influenced by the classical complement pathway. The company’s research revolves around C1q, a key molecule that, when aberrantly activated, contributes to various disease processes. Its lead product candidates include ANX005, a monoclonal antibody designed for intravenous administration, which has completed Phase 1b trials for treating Guillain-Barré syndrome, and ANX007, formulated for intravitreal use, which has also completed Phase 1b trials aimed at glaucoma treatment. Additionally, Annexon is advancing preclinical candidates targeting conditions such as warm autoimmune hemolytic anemia, Huntington's disease, amyotrophic lateral sclerosis, and geographic atrophy. Founded in 2011 and headquartered in South San Francisco, California, the company employs a biomarker-driven strategy to ensure effective engagement of its therapies in the intended patient populations.

Atento S.A. is a leading provider of customer relationship management (CRM) and business process outsourcing (BPO) services, operating primarily in Latin America and extending its reach to Europe, the Middle East, and Africa. The company offers a comprehensive suite of front and back-end services, including sales, customer care, technical support, collections, and back-office operations. Atento serves a diverse array of industries, such as telecommunications, banking, financial services, consumer goods, public administration, healthcare, and logistics. Its services are delivered through various digital channels, including SMS, email, chats, social media, and apps, as well as traditional voice interactions. With a strong operational presence, particularly in Latin America and Spain, Atento is well-positioned to support clients in their local markets, enhancing business efficiency and customer experience. The company's workforce of over 160,000 employees is integral to its success, contributing to its reputation as a top employer and a trusted partner for businesses seeking to meet evolving consumer demands.

CargoX is a technology freight marketplace that provides shipping companies and carriers a smart and efficient solution to transport the most diverse types of products in any parts of Brazil. Through technology, we connect over 10 thousand shippers with 1.4 million trucks to eliminate excess capacity. CargoX save on shipping costs for shippers, increase earnings for truckers and reduces C02 emissions generated by empty trucks on the road. CargoX was founded on 2013 and is headquartered in Sao Paulo, Brazil.

CargoX is a technology freight marketplace that provides shipping companies and carriers a smart and efficient solution to transport the most diverse types of products in any parts of Brazil. Through technology, we connect over 10 thousand shippers with 1.4 million trucks to eliminate excess capacity. CargoX save on shipping costs for shippers, increase earnings for truckers and reduces C02 emissions generated by empty trucks on the road. CargoX was founded on 2013 and is headquartered in Sao Paulo, Brazil.

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the discovery and development of therapies for fibrotic diseases. The company's lead candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, currently being developed for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both conditions and is undergoing Phase 2a trials for IPF, with plans for a Phase 2a trial in PSC. Pliant is also advancing PLN-1474, a small-molecule selective inhibitor of avß1, aimed at treating liver fibrosis associated with nonalcoholic steatohepatitis, which is in Phase 1 clinical trials and has a partnership with Novartis. In addition to these clinical efforts, Pliant has two preclinical programs targeting oncology and muscular dystrophies. Founded in 2015, Pliant Therapeutics is committed to addressing unmet medical needs in the field of fibrosis.

Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing gene therapies aimed at treating both rare and prevalent diseases. Established in 2016, the company focuses on conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. Generation Bio employs an innovative non-viral platform that includes a proprietary high-capacity DNA construct known as closed-ended DNA (ceDNA), a cell-targeted lipid nanoparticle delivery system (ctLNP), and a scalable, capsid-free manufacturing process. This approach allows for the targeted delivery of genetic materials, including large and multiple genes across various tissues, and enables redosable treatments tailored to individual patient needs. By enhancing access to therapies for rare diseases and addressing more common conditions, Generation Bio aims to provide durable and sustainable treatment options for patients throughout their lives.

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

Beta Bionics is a biotechnology company based in Boston, Massachusetts, focused on advancing diabetes care through its innovative bionic pancreas system, known as the iLet. Founded in 2015, the company has developed a dual-chamber infusion pump that precisely delivers insulin and glucagon, allowing for autonomous management of blood sugar levels. The iLet has received breakthrough designation for its various configurations, including insulin-only, glucagon-only, and bihormonal uses, particularly in conjunction with Zealand Pharma’s dasiglucagon, a stable glucagon analog in a ready-to-use solution. By reducing the burden and cost associated with diabetes management, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

Full Truck Alliance is a platform that connects shippers with truckers to facilitate shipments across distance ranges and cargo weights. its revenues principally from shippers' and truckers' use of its platforms in connection with freight matching services.

Meituan Bike (formerly Mobike) is a Chinese fully station-less bicycle-sharing system. It develops mobile apps for users to find and use bicycles to travel anywhere. Davis Wang Xiao Feng, Hu Wei Wei, and Xia Yi Ping founded Mobike on January 27, 2015, with its headquarters in Beijing, China. Mobike raised $600 million in Series E funding led by Tencent, bringing the firm's fundraising in 2017 alone to nearly US$1 billion in June 2017. It became worth US$3 billion in the same month. Chinese web company Meituan-Dianping acquired Mobike for US$2.7 billion in April 2018. Parent company Meituan-Dianping announced name change from Mobike to Meituan Bike on January 23, 2019 as part of an ongoing integration.

Sea Limited is an internet platform company headquartered in Singapore, primarily focused on the Greater Southeast Asia region, including countries like Indonesia, Vietnam, and Thailand. Founded in 2009, Sea operates three main business segments: digital entertainment, e-commerce, and digital financial services. Its Garena platform offers access to a wide range of mobile and PC online games, eSports operations, and various entertainment content, fostering a vibrant community through features like livestreaming and user forums. The Shopee platform serves as a mobile-centric e-commerce marketplace, providing integrated payment and logistics solutions to sellers. Additionally, SeaMoney delivers digital financial services, including e-wallets and payment processing, enhancing financial accessibility for individuals and businesses. Sea's mission is to improve the lives of consumers and small businesses in its region through technology, reflecting its commitment to connect users and promote growth in Southeast Asia.

The renewable energy arm of Hindustan Power Projects Pvt. Ltd .

Gojek, founded in 2010 and headquartered in Jakarta, Indonesia, operates as a Super App that offers a wide range of services, including food delivery, transportation, digital payments, shopping, and various on-demand services. Launched in 2015, the Gojek app has rapidly become the largest consumer transactional technology platform in Southeast Asia, driven by its focus on speed, innovation, and social impact. The company aims to empower the informal sector in the region while serving diverse markets such as transport, logistics, food, and entertainment. Gojek has established itself as a leading player in the on-demand economy, contributing significantly to the growth of digital services in Southeast Asia.

Nexvet Australia Pty Ltd, a biopharmaceutical company, develops biological therapies for companion animals. It develops drugs in the areas of chronic pain, immune oncology, chronic inflammation, and allergy. Nexvet Australia Pty Ltd was formerly known as Nexvet Biopharma Pty Ltd. The company was founded in 2010 and is based in Melbourne, Australia with a biopharmaceutical manufacturing facility in Tullamore, Ireland. Nexvet Australia Pty Ltd operates as a subsidiary of Zoetis Inc.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic diseases that require long-term treatment. The company is known for its innovative Medici Drug Delivery System, which utilizes subcutaneous delivery methods to provide steady dosing of therapeutic agents, particularly for conditions such as type 2 diabetes and obesity. Its flagship product, ITCA 650, is currently in a phase 3 clinical program aimed at improving treatment outcomes for diabetes patients through a unique delivery mechanism. In addition to diabetes, Intarcia is engaged in research and development for therapies targeting autoimmune disorders and other chronic conditions. Founded in 1995 and headquartered in Boston, Massachusetts, Intarcia also has a manufacturing facility in Hayward, California, and a research center in Durham, North Carolina.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic diseases that require long-term treatment. The company is known for its innovative Medici Drug Delivery System, which utilizes subcutaneous delivery methods to provide steady dosing of therapeutic agents, particularly for conditions such as type 2 diabetes and obesity. Its flagship product, ITCA 650, is currently in a phase 3 clinical program aimed at improving treatment outcomes for diabetes patients through a unique delivery mechanism. In addition to diabetes, Intarcia is engaged in research and development for therapies targeting autoimmune disorders and other chronic conditions. Founded in 1995 and headquartered in Boston, Massachusetts, Intarcia also has a manufacturing facility in Hayward, California, and a research center in Durham, North Carolina.

Youku is a prominent Chinese video-sharing platform that allows users to search, view, and share high-quality video content on various devices. It employs a tri-networks integration model, offering a diverse range of content that includes user-generated videos, self-produced series, licensed professional material, television dramas, movies, news reports, variety shows, and music videos. The platform serves as a space for individuals and institutions to upload and share their creative works and personal moments. Youku significantly expanded its reach after acquiring Tudou, becoming Youku Tudou, Inc. The company has faced competition from other major platforms such as Tencent Video, 163 Video, and Sohu Video. Since its inception, Youku has garnered substantial user engagement, with millions of daily active viewers, establishing itself as a key player in the online video landscape in China.

Sohu provides a network of community-based, web 2.0 products to millions of Chinese users on a daily basis. Sohu corporate services consist of online brand advertising on its matrix of websites as well as bid listing and home page on its in-house developed search directory and engine. This matrix of Chinese language web properties and proprietary search engines, consists of the mass portal and online media destination sohu.com, interactive search engine sogou.com, the games information portal 17173.com, the real estate website focus.cn, developer and operator of online games www.changyou.com/en/ and online video website tv.sohu.com. It also provides multiple news and information service on mobile platforms, including Sohu News app and mobile news portal WAP.Sohu.com. Sohu's online game subsidiary, Changyou.com has a diverse portfolio of online games that includes Tian Long Ba Bu, a massively multiplayer online games in China, and DDTank and Wartune (also known as Shen Qu), which are two popular web games in China. Sohu.com was established in November 1995 and went public in July 2000.

AdsIt is a provider of online video ads.

Youku is a prominent Chinese video-sharing platform that allows users to search, view, and share high-quality video content on various devices. It employs a tri-networks integration model, offering a diverse range of content that includes user-generated videos, self-produced series, licensed professional material, television dramas, movies, news reports, variety shows, and music videos. The platform serves as a space for individuals and institutions to upload and share their creative works and personal moments. Youku significantly expanded its reach after acquiring Tudou, becoming Youku Tudou, Inc. The company has faced competition from other major platforms such as Tencent Video, 163 Video, and Sohu Video. Since its inception, Youku has garnered substantial user engagement, with millions of daily active viewers, establishing itself as a key player in the online video landscape in China.

Beijing Adsit Technology CO., LTD. offers big data based Internet marketing solutions. The company offers precision Internet advertising services, such as social media advertising and performance marketing services. It also engages in content marketing services through e-commerce platforms; multi-platform content distribution; and developing live broadcast platform for promotion services. Additionally, it produces shopping guide videos. Beijing Adsit Technology CO., LTD. was founded in 2006 and is based in Beijing, China.

Youku is a prominent Chinese video-sharing platform that allows users to search, view, and share high-quality video content on various devices. It employs a tri-networks integration model, offering a diverse range of content that includes user-generated videos, self-produced series, licensed professional material, television dramas, movies, news reports, variety shows, and music videos. The platform serves as a space for individuals and institutions to upload and share their creative works and personal moments. Youku significantly expanded its reach after acquiring Tudou, becoming Youku Tudou, Inc. The company has faced competition from other major platforms such as Tencent Video, 163 Video, and Sohu Video. Since its inception, Youku has garnered substantial user engagement, with millions of daily active viewers, establishing itself as a key player in the online video landscape in China.

E-House (China) Enterprise Holdings Limited, an investment holding company, provides real estate transaction services in China. It primarily offers real estate agency, real estate data and consulting, and real estate brokerage network services to real estate developers, brokerage firms, banks, investors, and government and non-profit organizations. The company also provides technology and information development and consulting services, and real estate marketing services. E-House (China) Enterprise Holdings Limited was founded in 2000 and is headquartered in Shanghai, China.

Heidi Coast Advertising Co., Ltd. is a Chinese company focused on the development and operation of campus media integrated marketing solutions. Heidi Coast Advertising’s leading brand, “China Campus Media,” covers new media such as campus video, campus outdoor, campus activity, CC176.com, and more. By cooperating with educational institutions and major domestic media organizations, the company spreads news, entertainment, programs, and advertisement information in universities and colleges, with students as the main audience group. It covers 18 economically developed cities and over 330 colleges and universities in China. It influences over 5 million people daily and maintains a campus broadcasting network.

Youku is a prominent Chinese video-sharing platform that allows users to search, view, and share high-quality video content on various devices. It employs a tri-networks integration model, offering a diverse range of content that includes user-generated videos, self-produced series, licensed professional material, television dramas, movies, news reports, variety shows, and music videos. The platform serves as a space for individuals and institutions to upload and share their creative works and personal moments. Youku significantly expanded its reach after acquiring Tudou, becoming Youku Tudou, Inc. The company has faced competition from other major platforms such as Tencent Video, 163 Video, and Sohu Video. Since its inception, Youku has garnered substantial user engagement, with millions of daily active viewers, establishing itself as a key player in the online video landscape in China.